Arbutus生物制药 ABUS 深 沪
等待开盘 07-01 09:30:00 美东时间
4.80
+0.120
+2.56%
华盛通- 最 高4.87
- 今 开4.70
- 成交量 337.29万股
- 最 低 4.67
- 昨 收 4.68
- 总市值 94.82万
- 52周最高 5.10
- 市盈率 静 --
- 换手率 1.71%
- 52周最低 3.08
- 委 比 -90.94%
- 总股本 0.00亿
- 历史最高 31.48
- 量 比 0.91
- 振 幅 4.27%
- 历史最低 0.821
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $(0.04) by 2275 percent. This is a 769.23 percent increase over losses of $(0.13) per share from
05-13 19:45
Arbutus Biopharma Q1 revenue surges on Moderna settlement
Arbutus Biopharma Q1 revenue surges on Moderna settlement Overview US infectious disease drugmaker's Q1 revenue surged on license revenue from Moderna litigation settlement Company posted net income of $169.7 mln, reversing a loss in the prior-year quarter Outlook Arbutus expects to receive $178.7 m
05-13 19:42
Arbutus Q1 FY26 net income turns to USD 169.7 million; revenue rises to USD 179.1 million
Arbutus Q1 FY26 net income turns to USD 169.7 million; revenue rises to USD 179.1 million Arbutus Biopharma Q1 2026 revenue more than doubled to USD 179.1 million, driven by USD 178.7 million in estimated license revenue tied to Genevant’s Moderna litigation settlement. Net income swung to USD 169.7
05-13 19:31
UPDATE 1-Moderna tops revenue estimates on stronger international COVID vaccine sales
UPDATE 1-Moderna tops revenue estimates on stronger international COVID vaccine sales International sales outpace US as partnerships boost revenue Q1 net loss includes charge from patent settlement with Genevant, Arbutus Moderna forecasts 10% revenue growth in 2026, with US share expected to decline
05-01 18:38
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales International sales outpace US as partnerships boost revenue Q1 net loss includes charge from patent settlement with Genevant, Arbutus Moderna forecasts 10% revenue growth in 2026, with US share expected to declin
05-01 18:30
Europe Clears First Flu/COVID Combo Shot From Moderna
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data showing strong immune response.
04-22 01:58
Arbutus Biopharma's Imdusiran Receives FDA's Fast Track Designation To Treat Chronic Hepatitis B
Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration ("FDA") has
04-15 19:33
Arbutus says FDA grants Fast Track designation for hepatitis B drug imdusiran
Arbutus says FDA grants Fast Track designation for hepatitis B drug imdusiran Arbutus Biopharma disclosed FDA Fast Track designation for imdusiran in chronic hepatitis B. Trial results were already presented, showing some patients reached a functional cure or stopped medication. Fast Track status co
04-15 19:32
Arbutus says FDA grants Fast Track designation for imdusiran in chronic hepatitis B
Arbutus says FDA grants Fast Track designation for imdusiran in chronic hepatitis B FDA granted Fast Track designation to Arbutus for imdusiran to treat chronic hepatitis B. Designation could speed development and FDA review for the program. Disclaimer: This news brief was created by Public Technolo
04-15 19:31
Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 85.71 percent increase over losses of $(0.07) per share from
03-23 19:44
